(Total Views: 653)
Posted On: 01/12/2021 12:17:22 AM
Post# of 148949
Several people, including myself, have pointed out that the FDA is much more concerned with clinical outcomes in a PIII... Nothing mind boggling about it; it's how they've operated since inception. This process has worked for decades, even before receptor occupancy could be a known quantity.
Classic example is Beta-Amyloid and Alzheimer's... The industry raced to find molecules to target BA, thinking clearing that would resolve Alzheimer's. They ran all sorts of molecular diagnostics as "corroborating data." This is where it ended up:
https://www.sciencemag.org/news/2019/03/anoth...has-failed
I'd give you the benefit of the doubt, that you have no medical or regulatory (and possibly pharma investing) experience, but the fact you keep repeating this same broken narrative.. and finally, you just came out and said it...
Your collective efforts, while persistent, are falling way short, and time is running out. Try harder.
Classic example is Beta-Amyloid and Alzheimer's... The industry raced to find molecules to target BA, thinking clearing that would resolve Alzheimer's. They ran all sorts of molecular diagnostics as "corroborating data." This is where it ended up:
https://www.sciencemag.org/news/2019/03/anoth...has-failed
I'd give you the benefit of the doubt, that you have no medical or regulatory (and possibly pharma investing) experience, but the fact you keep repeating this same broken narrative.. and finally, you just came out and said it...
Quote:
This post by MDV brings to my mind two mind boggling CD12 scenarios.
....
What if some data is done, but Cytodyn doesn't have it because of their spat with Patterson?
Read More: https://investorshangout.com/post/newpost/605...to=6015347
Your collective efforts, while persistent, are falling way short, and time is running out. Try harder.
(7)
(0)Scroll down for more posts ▼
